Cerebral small vessel disease and Alzheimer’s disease

Clinical Interventions in Aging

Volumn 10, Issue , 2015, Pages 1695-1704

  Cai, Zhiyou ^a   Wang, Chuanling ^a   He, Wenbo ^a   Tu, Hanjun ^a   Tang, Zhengang ^a   Xiao, Ming ^b   Yan, Liang Jun ^c  

^a HUBEI UNIVERSITY OF MEDICINE   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Cerebral microbleeds; Cerebrovascular diseases; Dementia; Lacunar infarct; Leukoaraiosis

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; CARRIER PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; SORL1 PROTEIN, HUMAN;

ALZHEIMER DISEASE; ARTERIOLE; BINSWANGER ENCEPHALOPATHY; BRAIN HEMORRHAGE; BRAIN SIZE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; LACUNAR STROKE; LEUKOARAIOSIS; MORPHOLOGY; MULTIINFARCT DEMENTIA; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; REVIEW; WHITE MATTER INJURY; AGING; ATROPHY; BRAIN; COGNITIVE DEFECT; DEMENTIA; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

AGING; ALZHEIMER DISEASE; ATROPHY; BRAIN; CEREBRAL SMALL VESSEL DISEASES; COGNITION DISORDERS; DEMENTIA; DEMENTIA, VASCULAR; HUMANS; LDL-RECEPTOR RELATED PROTEINS; LEUKOARAIOSIS; MEMBRANE TRANSPORT PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; STROKE, LACUNAR;

EID: 84945900841     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S90871     Document Type: Review

References (151)

1. Vinters HV. Emerging concepts in Alzheimer’s disease. Annu Rev Pathol. 2015;10:291–319.
2. Wurtman R. Biomarkers in the diagnosis and management of Alzheimer’s disease. Metabolism. 2015;64(3 suppl 1):S47–S50.
3. Bloom GS. Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014;71(4):505–508.
4. Cai Z. Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer’s disease (Review). Mol Med Rep. 2014;9(5):1533–1541.
5. Tomimoto H. [Vascular cognitive impairment: the relationship between hypertensive small vessel disease and cerebral amyloid angiopathy]. Brain Nerve. 2012;64(12):1377–1386. Japanese.
6. de la Torre JC. Cardiovascular risk factors promote brain hypoperfusion leading to cognitive decline and dementia. Cardiovasc Psychiatry Neurol. 2012;2012:367516.
7. Pasquier F, Boulogne A, Leys D, Fontaine P. Diabetes mellitus and dementia. Diabetes Metab. 2006;32(5 pt 1):403–414.
8. Palacio S, McClure LA, Benavente OR, Bazan C 3rd, Pergola P, Hart RG. Lacunar strokes in patients with diabetes mellitus: risk factors, infarct location, and prognosis: the secondary prevention of small subcortical strokes study. Stroke. 2014;45(9):2689–2694.
9. Zheng L, Vinters HV, Mack WJ, Zarow C, Ellis WG, Chui HC. Cerebral atherosclerosis is associated with cystic infarcts and microinfarcts but not Alzheimer pathologic changes. Stroke. 2013;44(10):2835–2841.
10. Siegel GJ, Chauhan NB, Feinstein DL, et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology. 2008;71(5): 383. Author reply 383.
11. Zhang M, Chen M, Wang Q, et al. Relationship between cerebral microbleeds and cognitive function in lacunar infarct. J Int Med Res. 2013;41(2):347–355.
12. Lammie GA, Brannan F, Slattery J, Warlow C. Nonhypertensive cerebral small-vessel disease. An autopsy study. Stroke. 1997;28(11): 2222–2229.
13. Schmidt H, Zeginigg M, Wiltgen M, et al. Genetic variants of the NOTCH3 gene in the elderly and magnetic resonance imaging correlates of age-related cerebral small vessel disease. Brain. 2011;134(pt 11):3384–3397.
14. Paquet C, Jouvent E, Mine M, et al. A cortical form of CADASIL with cerebral Abeta amyloidosis. Acta Neuropathol. 2010;120(6): 813–820.
15. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9(7):689–701.
16. Schmidtke K, Hull M. Cerebral small vessel disease: how does it progress? J Neurol Sci. 2005;22(9–230):13–20.
17. Zhang AJ, Yu XJ, Wang M. The clinical manifestations and pathophysiology of cerebral small vessel disease. Neurosci Bull. 2010;26(3): 257–264.
18. Lammie GA. Hypertensive cerebral small vessel disease and stroke. Brain Pathol. 2002;12(3):358–370.
19. Onodera O. [What is cerebral small vessel disease?]. Rinsho Shinkeigaku. 2011;51(6):399–405. Japanese.
20. Yates PA, Villemagne VL, Ellis KA, Desmond PM, Masters CL, Rowe CC. Cerebral microbleeds: a review of clinical, genetic, and neuroimaging associations. Front Neurol. 2014;4:205.
21. Iadecola C. Rescuing troubled vessels in Alzheimer disease. Nat Med. 2005;11(9):923–924.
22. Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol. 2010; 120(3):287–296.
23. Lockhart A, Lamb JR, Osredkar T, et al. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain. 2007;130(pt 10):2607–2615.
24. Iadecola C. Cerebrovascular effects of amyloid-beta peptides: mechanisms and implications for Alzheimer’s dementia. Cell Mol Neurobiol. 2003;23(4–5):681–689.
25. Roher AE, Kuo YM, Esh C, et al. Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer’s disease. Mol Med. 2003;9(3–4):112–122.
26. Brown WR, Thore CR. Review: cerebral microvascular pathology in ageing and neurodegeneration. Neuropathol Appl Neurobiol. 2011; 37(1):56–74.
27. Roher AE, Esh C, Kokjohn TA, et al. Circle of Willis atherosclerosis is a risk factor for sporadic Alzheimer’s disease. Arterioscler Thromb Vasc Biol. 2003;23(11):2055–2062.
28. Yarchoan M, Xie SX, Kling MA, et al. Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain. 2012;135(pt 12):3749–3756.
29. Girouard H, Iadecola C. Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. J Appl Physiol (1985).2006;100(1):328–335.
30. Henry-Feugeas MC. Alzheimer’s disease in late-life dementia: a minor toxic consequence of devastating cerebrovascular dysfunction. Med Hypotheses. 2008;70(4):866–875.
31. Sacco S, Marini C, Totaro R, Russo T, Cerone D, Carolei A. A population-based study of the incidence and prognosis of lacunar stroke. Neurology. 2006;66(9):1335–1338.
32. Lastilla M. Lacunar infarct. Clin Exp Hypertens. 2006;28(3–4):205–215.
33. Das T, Settecase F, Boulos M, et al. Multimodal CT provides improved performance for lacunar infarct detection. AJNR Am J Neuroradiol. 2015;36(6):1069–1075.
34. Labovitz DL, Boden-Albala B, Hauser WA, Sacco RL. Lacunar infarct or deep intracerebral hemorrhage: who gets which? The Northern Manhattan study. Neurology. 2007;68(8):606–608.
35. Masana Y, Iwamoto F, Yamada M, Motozaki T, Yoshimine T. [Prevalence and risk factors for silent lacunar infarct in white matter lesion – brain multiphasic screening]. No To Shinkei. 2003;55(12):1027–1032. Japanese.
36. Arboix A. Lacunar infarct and cognitive decline. Expert Rev Neurother. 2011;11(9):1251–1254.
37. van Zandvoort MJ, van der Grond J, Kappelle LJ, de Haan EH. Cognitive deficits and changes in neurometabolites after a lacunar infarct. J Neurol. 2005;252(2):183–190.
38. Chen CF, Lan SH, Khor GT, Lai CL, Tai CT. Cognitive dysfunction after acute lacunar infarct. Kaohsiung J Med Sci. 2005;21(6):267–271.
39. Grinberg LT, Thal DR. Vascular pathology in the aged human brain. Acta Neuropathol. 2010;119(3):277–290.
40. Benisty S, Gouw AA, Porcher R, et al. Location of lacunar infarcts correlates with cognition in a sample of non-disabled subjects with age-related white-matter changes: the LADIS study. J Neurol Neurosurg Psychiatry. 2009;80(5):478–483.
41. Wen HM, Mok VC, Fan YH, et al. Effect of white matter changes on cognitive impairment in patients with lacunar infarcts. Stroke. 2004;35(8):1826–1830.
42. Nagata K, Takano D, Yamazaki T, et al. Cerebrovascular lesions in elderly Japanese patients with Alzheimer’s disease. J Neurol Sci. 2012;322(1–2):87–91.
43. Whitehead SN, Massoni E, Cheng G, et al. Triflusal reduces cerebral ischemia induced inflammation in a combined mouse model of Alzheimer’s disease and stroke. Brain Res. 2010;1366:246–256.
44. Richard E, Gouw AA, Scheltens P, van Gool WA. Vascular care in patients with Alzheimer disease with cerebrovascular lesions slows progression of white matter lesions on MRI: the evaluation of vascular care in Alzheimer’s disease (EVA) study. Stroke. 2010;41(3):554–556.
45. Gold G, Giannakopoulos P, Herrmann FR, Bouras C, Kovari E. Identification of Alzheimer and vascular lesion thresholds for mixed dementia. Brain. 2007;130(pt 11):2830–2836.
46. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun study. JAMA. 1997;277(10):813–817.
47. Heyman A, Fillenbaum GG, Welsh-Bohmer KA, et al. Cerebral infarcts in patients with autopsy-proven Alzheimer’s disease: CERAD, part XVIII. Consortium to establish a registry for Alzheimer’s disease. Neurology. 1998;51(1):159–162.
48. van Rooden S, Goos JD, van Opstal AM, et al. Increased number of microinfarcts in Alzheimer disease at 7-T MR imaging. Radiology. 2014;270(1):205–211.
49. Kester MI, Goos JD, Teunissen CE, et al. Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers. JAMA Neurol. 2014;71(7):855–862.
50. Erten-Lyons D, Woltjer R, Kaye J, et al. Neuropathologic basis of white matter hyperintensity accumulation with advanced age. Neurology. 2013;81(11):977–983.
51. Gurol ME, Irizarry MC, Smith EE, et al. Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology. 2006;66(1):23–29.
52. De Reuck JL, Cordonnier C, Deramecourt V, et al. Microbleeds in postmortem brains of patients with Alzheimer disease: a T2*-weighted gradient-echo 7.0 T magnetic resonance imaging study. Alzheimer Dis Assoc Disord. 2013;27(2):162–167.
53. Yakushiji Y, Hara H. [Cerebral microbleeds: clinical features and management]. Rinsho Shinkeigaku. 2012;52(11):1106–1109. Japanese.
54. Park JH, Seo SW, Kim C, et al. Pathogenesis of cerebral microbleeds: in vivo imaging of amyloid and subcortical ischemic small vessel disease in 226 individuals with cognitive impairment. Ann Neurol. 2013;73(5):584–593.
55. Ghelmez D, Sorin Tuta S, Popa C. Cerebral microbleeds (CMBs) – relevance for mechanisms of cerebral hemorrhage – analysis of 24 MRI evaluated patients. J Med Life. 2013;6(4):437–439.
56. Shams S, Martola J, Granberg T, et al. Cerebral microbleeds: different prevalence, topography, and risk factors depending on dementia diagnosis – the Karolinska Imaging Dementia Study. AJNR Am J Neuroradiol. 2015;36(4):661–666.
57. Nagasawa J, Kiyozaka T, Ikeda K. Prevalence and clinicoradiological analyses of patients with Alzheimer disease coexisting multiple microbleeds. J Stroke Cerebrovasc Dis. 2014;23(9):2444–2449.
58. Goos JD, Kester MI, Barkhof F, et al. Patients with Alzheimer disease with multiple microbleeds: relation with cerebrospinal fluid biomarkers and cognition. Stroke. 2009;40(11):3455–3460.
59. Heringa SM, Reijmer YD, Leemans A, Koek HL, Kappelle LJ, Biessels GJ. Multiple microbleeds are related to cerebral network disruptions in patients with early Alzheimer’s disease. J Alzheimers Dis. 2014;38(1):211–221.
60. Whitwell JL, Kantarci K, Weigand SD, et al. Microbleeds in atypical presentations of Alzheimer’s disease: a comparison to dementia of the Alzheimer’s type. J Alzheimers Dis. 2015;45(4):1109–1117.
61. Nakata-Kudo Y, Mizuno T, Yamada K, et al. Microbleeds in Alzheimer disease are more related to cerebral amyloid angiopathy than cerebrovascular disease. Dement Geriatr Cogn Disord. 2006;22(1):8–14.
62. Martinez-Ramirez S, Greenberg SM, Viswanathan A. Cerebral microbleeds: overview and implications in cognitive impairment. Alzheimers Res Ther. 2014;6(3):33.
63. Stone J, Johnstone DM, Mitrofanis J, O’Rourke M. The mechanical cause of age-related dementia (Alzheimer’s disease): the brain is destroyed by the pulse. J Alzheimers Dis. 2015;44(2):355–373.
64. Benedictus MR, Goos JD, Binnewijzend MA, et al. Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer’s disease. Neurobiol Aging. 2013;34(11):2488–2494.
65. Goos JD, Teunissen CE, Veerhuis R, et al. Microbleeds relate to altered amyloid-beta metabolism in Alzheimer’s disease. Neurobiol Aging. 2012;33(5):1011.e1011–e1019.
66. Yates PA, Desmond PM, Phal PM, et al. Incidence of cerebral microbleeds in preclinical Alzheimer disease. Neurology. 2014;82(14): 1266–1273.
67. Olazaran J, Ramos A, Boyano I, et al. Pattern of and risk factors for brain microbleeds in neurodegenerative dementia. Am J Alzheimers Dis Other Demen. 2014;29(3):263–269.
68. Brundel M, Heringa SM, de Bresser J, et al. High prevalence of cerebral microbleeds at 7Tesla MRI in patients with early Alzheimer’s disease. J Alzheimers Dis. 2012;31(2):259–263.
69. Wen Y, Miyashita A, Kitamura N, et al. SORL1 is genetically associated with neuropathologically characterized late-onset Alzheimer’s disease. J Alzheimers Dis. 2013;35(2):387–394.
70. Feng X, Hou D, Deng Y, Li W, Tian M, Yu Z. SORL1 gene polymorphism association with late-onset Alzheimer’s disease. Neurosci Lett. 2015;584:382–389.
71. Yin RH, Yu JT, Tan L. The role of SORL1 in Alzheimer’s disease. Mol Neurobiol. 2015;51(3):909–918.
72. Xue X, Zhang M, Lin Y, Xu E, Jia J. Association between the SORL1 rs2070045 polymorphism and late-onset Alzheimer’s disease: interaction with the ApoE genotype in the Chinese Han population. Neurosci Lett. 2014;559:94–98.
73. Felsky D, Szeszko P, Yu L, et al. The SORL1 gene and convergent neural risk for Alzheimer’s disease across the human lifespan. Mol Psychiatry. 2014;19(10):1125–1132.
74. Louwersheimer E, Ramirez A, Cruchaga C, et al. The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer’s disease. Neurobiol Aging. 2015;36(3):1605.e1613–e1620.
75. Schuur M, van Swieten JC, Schol-Gelok S, et al. Genetic risk factors for cerebral small-vessel disease in hypertensive patients from a genetically isolated population. J Neurol Neurosurg Psychiatry. 2011;82(1):41–44.
76. Cordonnier C. Brain microbleeds. Pract Neurol. 2010;10(2):94–100.
77. Loitfelder M, Seiler S, Schwingenschuh P, Schmidt R. Cerebral microbleeds: a review. Panminerva Med. 2012;54(3):149–160.
78. Hommet C, Mondon K, Constans T, et al. Review of cerebral microangiopathy and Alzheimer’s disease: relation between white matter hyperintensities and microbleeds. Dement Geriatr Cogn Disord. 2011;32(6):367–378.
79. Cordonnier C, van der Flier WM. Brain microbleeds and Alzheimer’s disease: innocent observation or key player? Brain. 2011;134(pt 2):335–344.
80. van der Flier WM. Clinical aspects of microbleeds in Alzheimer’s disease. J Neurol Sci. 2012;322(1–2):56–58.
81. O’Sullivan M. Leukoaraiosis. Pract Neurol. 2008;8(1):26–38.
82. Auriel E, Bornstein NM, Berenyi E, et al. Clinical, radiological and pathological correlates of leukoaraiosis. Acta Neurol Scand. 2011; 123(1):41–47.
83. Huang YH, Zhang WW, Lin L, et al. Could changes in arterioles impede the perivascular drainage of interstitial fluid from the cerebral white matter in leukoaraiosis? Neuropathol Appl Neurobiol. 2010;36(3):237–247.
84. Uh J, Yezhuvath U, Cheng Y, Lu H. In vivo vascular hallmarks of diffuse leukoaraiosis. J Magn Reson Imaging. 2010;32(1):184–190.
85. Bogousslavsky J. [Leukoencephalopathy, leukoaraiosis and cerebral infarction]. Rev Neurol (Paris). 1988;144(1):11–17. Japanese.
86. Duron E, Vidal JS, Bounatiro S, et al. Relationships between personality traits, medial temporal lobe atrophy, and white matter lesion in subjects suffering from mild cognitive impairment. Front Aging Neurosci. 2014;6:195.
87. Pluta R, Januszewski S, Ulamek M. Ischemic blood-brain barrier and amyloid in white matter as etiological factors in leukoaraiosis. Acta Neurochir Suppl. 2008;102:353–356.
88. Moody DM, Brown WR, Challa VR, Ghazi-Birry HS, Reboussin DM. Cerebral microvascular alterations in aging, leukoaraiosis, and Alzheimer’s disease. Ann N Y Acad Sci. 1997;826:103–116.
89. Coffman JA, Torello MW, Bornstein RA, Chakeres D, Burns E, Nasrallah HA. Leukoaraiosis in asymptomatic adult offspring of individuals with Alzheimer’s disease. Biol Psychiatry. 1990;27(11):1244–1248.
90. Diaz JF, Merskey H, Hachinski VC, et al. Improved recognition of leukoaraiosis and cognitive impairment in Alzheimer’s disease. Arch Neurol. 1991;48(10):1022–1025.
91. Sarabia-Cobo CM, Perez V, Hermosilla C, Nunez MJ, de Lorena P. Apathy and leukoaraiosis in mild cognitive impairment and Alzheimer’s disease: multicenter diagnostic criteria according to the latest studies. Dement Geriatr Cogn Dis Extra. 2014;4(2):228–235.
92. Chung CP, Beggs C, Wang PN, et al. Jugular venous reflux and white matter abnormalities in Alzheimer’s disease: a pilot study. J Alzheimers Dis. 2014;39(3):601–609.
93. Chen W, Song X, Zhang Y. Assessment of the Virchow-Robin spaces in Alzheimer disease, mild cognitive impairment, and normal aging, using high-field MR imaging. AJNR Am J Neuroradiol. 2011;32(8):1490–1495.
94. Makedonov I, Black SE, MacIntosh BJ. Cerebral small vessel disease in aging and Alzheimer’s disease: a comparative study using MRI and SPECT. Eur J Neurol. 2013;20(2):243–250.
95. Verdelho A, Madureira S, Moleiro C, et al. Self-perceived memory complaints predict progression to Alzheimer disease. The LADIS study. J Alzheimers Dis. 2011;27(1):491–498.
96. van Swieten JC, Caplan LR. Binswanger’s disease. Adv Neurol. 1993;62:193–211.
97. Schorer CE. Alzheimer and Kraepelin describe Binswanger’s disease. J Neuropsychiatry Clin Neurosci. 1992;4(1):55–58.
98. Ferrer I, Bella R, Serrano MT, Marti E, Guionnet N. Arteriolosclerotic leucoencephalopathy in the elderly and its relation to white matter lesions in Binswanger’s disease, multi-infarct encephalopathy and Alzheimer’s disease. J Neurol Sci. 1990;98(1):37–50.
99. Peterson B, Summergrad P. Binswanger’s disease (Part II): pathogenesis of subcortical arteriosclerotic encephalopathy and its relation to other dementing processes. J Geriatr Psychiatry Neurol. 1989;2(4):171–181.
100. Fisher CM. Binswanger’s encephalopathy: a review. J Neurol. 1989;236(2):65–79.
101. Sandyk R. Subcortical arteriosclerotic encephalopathy (Binswanger’s disease). S Afr Med J. 1983;63(6):204–205.
102. Tomimoto H, Akiguchi I, Akiyama H, et al. Vascular changes in white matter lesions of Alzheimer’s disease. Acta Neuropathol. 1999;97(6):629–634.
103. Kosaka K, Ikeda K, Matsushita M, Iizuka R. A combination of Alzheimer’s and Binswanger’s diseases – a clinicopathological study of four cases. Jpn J Psychiatry Neurol. 1986;40(4):685–692.
104. Watanabe T, Shiino A, Akiguchi I. Absolute quantification in proton magnetic resonance spectroscopy is superior to relative ratio to discriminate Alzheimer’s disease from Binswanger’s disease. Dement Geriatr Cogn Disord. 2008;26(1):89–100.
105. Leung KK, Bartlett JW, Barnes J, Manning EN, Ourselin S, Fox NC. Cerebral atrophy in mild cognitive impairment and Alzheimer disease: rates and acceleration. Neurology. 2013;80(7):648–654.
106. Beck C, Kruetzelmann A, Forkert ND, et al. A simple brain atrophy measure improves the prediction of malignant middle cerebral artery infarction by acute DWI lesion volume. J Neurol. 2014;261(6): 1097–1103.
107. Henny C, Despland PA, Regli F. [Initial epileptic crisis after the age of 60: etiology, clinical aspects and EEG]. Schweiz Med Wochenschr. 1990;120(21):787–792. Japanese.
108. Bigler ED. The clinical significance of cerebral atrophy in traumatic brain injury. Arch Clin Neuropsychol. 1987;2(3):293–304.
109. Tate DF, Khedraki R, Neeley ES, Ryser DK, Bigler ED. Cerebral volume loss, cognitive deficit, and neuropsychological performance: comparative measures of brain atrophy: II. Traumatic brain injury. J Int Neuropsychol Soc. 2011;17(2):308–316.
110. Aoi MC, Hu K, Lo MT, Selim M, Olufsen MS, Novak V. Impaired cerebral autoregulation is associated with brain atrophy and worse functional status in chronic ischemic stroke. PLoS One. 2012;7(10): e46794.
111. Dell’Oglio E, Ceccarelli A, Glanz BI, et al. Quantification of global cerebral atrophy in multiple sclerosis from 3T MRI using SPM: the role of misclassification errors. J Neuroimaging. 2015;25(2): 191–199.
112. Cordato NJ, Duggins AJ, Halliday GM, Morris JG, Pantelis C. Clinical deficits correlate with regional cerebral atrophy in progressive supranuclear palsy. Brain. 2005;128(pt 6):1259–1266.
113. Kassubek J, Bernhard Landwehrmeyer G, Ecker D, et al. Global cerebral atrophy in early stages of Huntington’s disease: quantitative MRI study. Neuroreport. 2004;15(2):363–365.
114. Aribisala BS, Valdes Hernandez MC, Royle NA, et al. Brain atrophy associations with white matter lesions in the ageing brain: the Lothian Birth Cohort 1936. Eur Radiol. 2013;23(4):1084–1092.
115. Sala S, Agosta F, Pagani E, Copetti M, Comi G, Filippi M. Microstructural changes and atrophy in brain white matter tracts with aging. Neurobiol Aging. 2012;33(3):488–498.e482.
116. Nitkunan A, Lanfranconi S, Charlton RA, Barrick TR, Markus HS. Brain atrophy and cerebral small vessel disease: a prospective follow-up study. Stroke. 2011;42(1):133–138.
117. Jokinen H, Lipsanen J, Schmidt R, et al. Brain atrophy accelerates cognitive decline in cerebral small vessel disease: the LADIS study. Neurology. 2012;78(22):1785–1792.
118. Thong JY, Hilal S, Wang Y, et al. Association of silent lacunar infarct with brain atrophy and cognitive impairment. J Neurol Neurosurg Psychiatry. 2013;84(11):1219–1225.
119. Wikgren M, Karlsson T, Soderlund H, et al. Shorter telomere length is linked to brain atrophy and white matter hyperintensities. Age Ageing. 2014;43(2):212–217.
120. Kanhai DA, de Kleijn DP, Kappelle LJ, et al. Extracellular vesicle protein levels are related to brain atrophy and cerebral white matter lesions in patients with manifest vascular disease: the SMART-MR study. BMJ Open. 2014;4(1):e003824.
121. Guo H, Song X, Vandorpe R, et al. Evaluation of common structural brain changes in aging and Alzheimer disease with the use of an MRI-based brain atrophy and lesion index: a comparison between T1WI and T2WI at 1.5T and 3T. AJNR Am J Neuroradiol. 2014;35(3):504–512.
122. Anandh KR, Sujatha CM, Ramakrishnan S. Atrophy analysis of corpus callosum in Alzheimer brain MR images using anisotropic diffusion filtering and level sets. Conf Proc IEEE Eng Med Biol Soc. 2014;2014:1945–1948.
123. Whitwell JL, Jack CR Jr, Pankratz VS, et al. Rates of brain atrophy over time in autopsy-proven frontotemporal dementia and Alzheimer disease. Neuroimage. 2008;39(3):1034–1040.
124. Sluimer JD, Vrenken H, Blankenstein MA, et al. Whole-brain atrophy rate in Alzheimer disease: identifying fast progressors. Neurology. 2008;70(19 pt 2):1836–1841.
125. Bokde AL, Pietrini P, Ibanez V, et al. The effect of brain atrophy on cerebral hypometabolism in the visual variant of Alzheimer disease. Arch Neurol. 2001;58(3):480–486.
126. Henneman WJ, Sluimer JD, Barnes J, et al. Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. Neurology. 2009;72(11):999–1007.
127. Prins ND, van Dijk EJ, den Heijer T, et al. Cerebral small-vessel disease and decline in information processing speed, executive function and memory. Brain. 2005;128(pt 9):2034–2041.
128. Sierra C. Cerebral small vessel disease, cognitive impairment and vascular dementia. Panminerva Med. 2012;54(3):179–188.
129. Pantoni L, Garcia JH. Cognitive impairment and cellular/vascular changes in the cerebral white matter. Ann N Y Acad Sci. 1997;826:92–102.
130. Richardson K, Stephan BC, Ince PG, Brayne C, Matthews FE, Esiri MM. The neuropathology of vascular disease in the medical research council cognitive function and ageing study (MRC CFAS). Curr Alzheimer Res. 2012;9(6):687–696.
131. Costanza A, Xekardaki A, Kovari E, Gold G, Bouras C, Giannakopoulos P. Microvascular burden and Alzheimer-type lesions across the age spectrum. J Alzheimers Dis. 2012;32(3):643–652.
132. Rincon F, Wright CB. Current pathophysiological concepts in cerebral small vessel disease. Front Aging Neurosci. 2014;6:24.
133. Meier IB, Manly JJ, Provenzano FA, et al. White matter predictors of cognitive functioning in older adults. J Int Neuropsychol Soc. 2012; 18(3):414–427.
134. Pasquier F, Leys D. Why are stroke patients prone to develop dementia? J Neurol. 1997;244(3):135–142.
135. Suades-Gonzalez E, Jodar-Vicente M, Perdrix-Solas D. [Memory deficit in patients with subcortical vascular cognitive impairment versus Alzheimer-type dementia: the sensitivity of the ‘word list’ subtest on the Wechsler Memory Scale-III]. Rev Neurol. 2009;49(12):623–629. Japanese.
136. Hilal S, Saini M, Tan CS, et al. Cerebral microbleeds and cognition: the epidemiology of dementia in Singapore study. Alzheimer Dis Assoc Disord. 2014;28(2):106–112.
137. De Deyn PP, Goeman J, Engelborghs S, et al. From neuronal and vascular impairment to dementia. Pharmacopsychiatry. 1999;32(suppl 1):17–24.
138. Kovacic JC, Fuster V. Atherosclerotic risk factors, vascular cognitive impairment, and Alzheimer disease. Mt Sinai J Med. 2012;79(6):664–673.
139. Erkinjuntti T. Diagnosis and management of vascular cognitive impairment and dementia. J Neural Transm Suppl. 2002;(63):91–109.
140. Attems J, Jellinger KA. The overlap between vascular disease and Alzheimer’s disease – lessons from pathology. BMC Med. 2014;12:206.
141. Henry-Feugeas MC. MRI of the ‘Alzheimer syndrome’. J Neuroradiol. 2007;34(4):220–227.
142. Cechetto DF, Hachinski V, Whitehead SN. Vascular risk factors and Alzheimer’s disease. Expert Rev Neurother. 2008;8(5):743–750.
143. Chalmers K, Wilcock G, Love S. Contributors to white matter damage in the frontal lobe in Alzheimer’s disease. Neuropathol Appl Neurobiol. 2005;31(6):623–631.
144. Ble A, Ranzini M, Zurlo A, et al. Leukoaraiosis is associated with functional impairment in older patients with Alzheimer’s disease but not vascular dementia. J Nutr Health Aging. 2006;10(1):31–35.
145. Ramirez J, Berezuk C, McNeely AA, Scott CJ, Gao F, Black SE. Visible Virchow-Robin spaces on magnetic resonance imaging of Alzheimer’s disease patients and normal elderly from the Sunnybrook Dementia Study. J Alzheimers Dis. 2015;43(2):415–424.
146. Guzman VA, Carmichael OT, Schwarz C, Tosto G, Zimmerman ME, Brickman AM. White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume among individuals with mild cognitive impairment. Alzheimers Dement. 2013;9(5 suppl):S124–S131.
147. Umegaki H. Pathophysiology of cognitive dysfunction in older people with type 2 diabetes: vascular changes or neurodegeneration? Age Ageing. 2010;39(1):8–10.
148. Brickman AM. Contemplating Alzheimer’s disease and the contribution of white matter hyperintensities. Curr Neurol Neurosci Rep. 2013;13(12):415.
149. Klohs J, Rudin M, Shimshek DR, Beckmann N. Imaging of cerebrovascular pathology in animal models of Alzheimer’s disease. Front Aging Neurosci. 2014;6:32.
150. Jellinger KA. Pathogenesis and treatment of vascular cognitive impairment. Neurodegener Dis Manag. 2014;4(6):471–490.
151. Targosz-Gajniak M, Siuda J, Ochudlo S, Opala G. Cerebral white matter lesions in patients with dementia – from MCI to severe Alzheimer’s disease. J Neurol Sci. 2009;283(1–2):79–82.